| Nov 16 |
We're Keeping An Eye On Jasper Therapeutics' (NASDAQ:JSPR) Cash Burn Rate
|
| Nov 13 |
Jasper Therapeutics to Participate at Upcoming Investor Conferences
|
| Nov 8 |
Analysts Bullish on Jasper Therapeutics as Briquilimab Trials Show Promise
|
| Nov 7 |
Jasper Therapeutics GAAP EPS of -$1.24 misses by $0.17
|
| Nov 7 |
Jasper Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
|
| Oct 14 |
Jasper gains 11% on data for briquilimab in urticaria
|
| Oct 14 |
Jasper Therapeutics Reports Positive Data from SPOTLIGHT Study of Briquilimab in Chronic Inducible Urticaria
|
| Sep 10 |
Jasper Therapeutics Announces Health Canada Clearance of Clinical Trial Application for Phase 1b/2a Study of Briquilimab in Asthma
|
| Sep 4 |
Jasper Therapeutics to Present at Present at Upcoming September Investor Conferences
|
| Aug 13 |
Jasper Therapeutics GAAP EPS of -$0.97
|
